Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
enGene Therapeutics Inc. - Common Stock
(NQ:
ENGN
)
1.820
-0.030 (-1.63%)
Streaming Delayed Price
Updated: 9:35 AM EDT, Sep 10, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
8,670
Open
1.850
Bid (Size)
1.810 (600)
Ask (Size)
1.820 (600)
Prev. Close
1.850
Today's Range
1.810 - 1.850
52wk Range
1.400 - 12.25
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
September 08, 2026
From
enGene Therapeutics Inc.
Via
Business Wire
enGene to Participate in Upcoming Investor Conferences
September 01, 2026
From
enGene Therapeutics Inc.
Via
Business Wire
Performance
YTD
-79.4%
-79.4%
1 Month
+4.0%
+4.0%
3 Month
+13.7%
+13.7%
6 Month
-73.5%
-73.5%
1 Year
-67.2%
-67.2%
More News
Read More
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market
↗
August 13, 2026
Via
MarketBeat
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026
August 04, 2026
From
enGene Therapeutics Inc.
Via
Business Wire
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
July 16, 2026
From
enGene Therapeutics Inc.
Via
Business Wire
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
June 15, 2026
From
enGene Therapeutics Inc.
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
June 02, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge
↗
May 30, 2026
Via
The Motley Fool
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean
↗
May 30, 2026
Via
The Motley Fool
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm
May 29, 2026
From
The Schall Law Firm
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
May 26, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
May 19, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares
↗
May 15, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Unusual volume stocks are being observed in Monday's session.
↗
May 11, 2026
Via
Chartmill
enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain
↗
May 08, 2026
Via
MarketBeat
Which stocks are experiencing notable movement on Thursday?
↗
May 07, 2026
Via
Chartmill
Top stock movements in today's session.
↗
May 07, 2026
Via
Chartmill
There are notable gap-ups and gap-downs in today's session.
↗
May 07, 2026
Via
Chartmill
Which stocks are moving before the opening bell on Thursday?
↗
May 07, 2026
Via
Chartmill
enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
May 07, 2026
From
enGene Therapeutics Inc.
Via
Business Wire
enGene Announces Name Change to enGene Therapeutics Inc.
April 07, 2026
From
enGene Therapeutics Inc.
Via
Business Wire
This Biotech Was Quietly Bought Before a $58 Per Share Takeout
↗
March 21, 2026
Via
The Motley Fool
enGene Reports First Quarter 2026 Financial Results and Provides Business Update
March 09, 2026
From
enGene Holdings Inc.
Via
Business Wire
enGene to Participate in Upcoming Investor Conferences
February 20, 2026
From
enGene Holdings Inc.
Via
Business Wire
enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 04, 2026
From
enGene Holdings Inc.
Via
Business Wire
Frequently Asked Questions
Is enGene Therapeutics Inc. - Common Stock publicly traded?
Yes, enGene Therapeutics Inc. - Common Stock is publicly traded.
What exchange does enGene Therapeutics Inc. - Common Stock trade on?
enGene Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for enGene Therapeutics Inc. - Common Stock?
The ticker symbol for enGene Therapeutics Inc. - Common Stock is ENGN on the Nasdaq Stock Market
What is the current price of enGene Therapeutics Inc. - Common Stock?
The current price of enGene Therapeutics Inc. - Common Stock is 1.820
When was enGene Therapeutics Inc. - Common Stock last traded?
The last trade of enGene Therapeutics Inc. - Common Stock was at 09/10/26 09:35 AM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
